Dr. Mousa contributed to the discovery and development of novel anti-platelet, anti-thrombotic therapies, noninvasive myocardial perfusion (Cardiolite) and thrombus imaging agents. He also contributed to the discovery of ultra-short acting beta blocker, Esmolol, the first Angiotensin Receptor Blocker Losartan. His work has been reported in over 1,000 peer-reviewed publications and holds over 350 US and International Patents. Dr. Mousa is also a Visiting Scholar at the Johns Hopkins University, and holds academic appointments at the State University of New York, and Rensselaer Polytechnic Institute, and President of R&D at Vascular Vision Pharmaceutical Co.